Efficacy and Safety of Lenvatinib as a Conversion Therapy for HCC

Inclusion Criteria: 1. Male or female aged 18-75; 2. The participant must have confirmed diagnosis of HCC histologically or clinically; 3. The participant must have at least one untreated intrahepatic lesion that can be evaluated by contrast-enhanced CT or MRI; 4. The BCLC stage B/C patients, more than 3 tumor nodes or have portal vein tumor thrombus (Vp3-Vp4 according to LCSGJ PVTT classification) or extrahepatic metastases limited to one organ and the number of metastases nodules is no more than 3; 5. ECOG PS 0-1 and Child-Pugh A; 6. Surgical resection is not the first choice according to MDT evaluation; 7. Written informed consent; Exclusion Criteria: 1. WBC\<4.0\*10\^9/L, HB\<80 g/L, PLT\<75\*10\^9/L and NEUT\<1.5×10\^9/L; 2. Coagulation function: (prothrombin time) international normalized ratio (INR) \>1.2; 3. Liver function: serum albumin (ALB)\<3.5 g/dl, total bilirubin (TBIL)\>1.5 times the upper limit of normal range, alanine aminotransferase and aspartate aminotransferase (ALT and AST)\>3 times the upper limit of normal range; renal function index: serum creatinine (CRE)\>1.5 times the upper limit of normal range; uncontrolled hypertension (\>150/90mm Hg); 4. Lymph node metastasis to hilar of lung or liver, or peripheral tissue adhesion; 5. Participated in other clinical trials 30 days before enrollment; 6. With ascites, hepatic encephalopathy, Gilbert syndrome, sclerosing cholangitis; 7. Suspected allergy to study drug; 8. With other organ dysfunction, it is not expected to be tolerated general anesthesia or hepatectomy; 9. Other conditions that the investigators considered not unsuitable for inclusion.